摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-1-(2,5-二甲基-1H-吡咯-3-基)-乙酮 | 19597-16-1

中文名称
2-氯-1-(2,5-二甲基-1H-吡咯-3-基)-乙酮
中文别名
——
英文名称
2-chloro-1-(2,5-dimethyl-1H-pyrrol-3-yl)ethan-1-one
英文别名
2-chloro-1-(2,5-dimethyl-1H-pyrrol-3-yl)ethanone
2-氯-1-(2,5-二甲基-1H-吡咯-3-基)-乙酮化学式
CAS
19597-16-1
化学式
C8H10ClNO
mdl
MFCD09040485
分子量
171.626
InChiKey
RUBYBHQAISBPNU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    151-152 °C(Solv: water (7732-18-5); methanol (67-56-1))
  • 沸点:
    306.0±37.0 °C(Predicted)
  • 密度:
    1.198±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.375
  • 拓扑面积:
    32.9
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933990090

反应信息

  • 作为反应物:
    描述:
    2-氯-1-(2,5-二甲基-1H-吡咯-3-基)-乙酮三乙胺N,N-二异丙基乙胺 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 28.0h, 生成 1-(2-((tert-butyldimethylsilyl)oxy)-2-(2,5-dimethyl-1H-pyrrol-3-yl)vinyl)-6-oxo-1,6-dihydropyridine-3-carbonitrile
    参考文献:
    名称:
    [EN] PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF
    [FR] COMPOSÉS À BASE DE PYRIDINONE ET DE PYRIDAZINONE ET UTILISATIONS MÉDICALES ASSOCIÉES
    摘要:
    本文提供的各种示例涉及到以下公式的化合物A-L1-Het1-L2-Cy1或其药用可接受的盐、多型体、前药、溶剂合物或包合物,其中:A为环烷基、芳基、芳基烷基或杂环烷基;Het1为含有至少两个杂原子的杂环烷基;Cy1为杂环烷基;L1为键、烷基、烯基或炔基连接物;L2为酰基或烷基连接物;A和Cy1不同。这些化合物在治疗纤维化疾病、异常血管渗漏和病理性血管生成方面具有用途。
    公开号:
    WO2019173790A1
点击查看最新优质反应信息

文献信息

  • Amide derivatives
    申请人:IMPERIAL CHEMICAL INDUSTRIES PLC
    公开号:EP0084941A1
    公开(公告)日:1983-08-03
    Amide derivatives of the formula wherein either R1 is aryl or heterocyclic and A is a direct link, or R1 is aryl or heterocyclic, or hydrogen, or halogeno, hydroxy, amino, guanidino, mercapto, carboxy, carbamoyl, or a substituted derivative thereof, and A1 is alkylene, alkenylene, cycloalkylene or cycloalkenylene; wherein X is carbonyl or hydroxymethylene or substituted derivatives thereof; wherein A2 is alkylene, alkenylene or alkylidene; wherein R2 is hydrogen or alkyl which is unsubsituted or which bears an aryl substituent, or R2 has the formula -Q2-R20 as defined below; wherein R3 is hydrogen, alkyl or a carbonyl-containing group; wherein R4 is hydrogen or alkyl which is unsubstituted or which bears a halogeno, hydroxy, amino, guanidino, carboxy, carbamoyl, mercapto, alkoxy, alkylamino, dialkylamino, cyclic amino, alkylthio, alkanoylamino, alkoxycarbonylamino, alkoxycarbonyl, aryl or heterocyclyl substituent; wherein -NR5-CR6R16-Q1-R10 is an amino acid residue, R5, R6 and R16 being defined in claim 1, wherein Q1 and Q2, which may be the same or different, each is carbonyl (-CO-) or methylene (-CH2-); and wherein R10 and R20, which may be the same or different, is hydroxy, amino or a substituted derivative thereof or hydroxyamino or arylthio; or a salt thereof where appropriate; processes for their manufacture and pharmaceutical compositions containing them. The compounds are inhibitors of angiotensin converting enzyme and may be used in the treatment of hypertension.
    式中的酰胺衍生物 其中 R1 为芳基或杂环且 A 为直接连接,或 R1 为芳基或杂环、或氢、或卤素、羟基、氨基、胍基、巯基、羧基、氨基甲酰基或其取代衍生物,且 A1 为亚烷基、亚烯基、环亚烷基或环烯基;其中 X 为羰基或羟甲基或其取代衍生物; 其中 A2 为亚烷基、亚烯基或亚烷基; 其中 R2 为氢或未取代的烷基或带有芳基取代基的烷基,或 R2 具有如下定义的式 -Q2-R20 ; 其中 R3 为氢、烷基或含羰基的基团;其中 R4 是氢或未取代的烷基,或带有卤素、羟基、氨基、胍基、羧基、氨基甲酰基、巯基、烷氧基、烷基氨基、二烷基氨基、环氨基、烷硫基、烷酰氨基、烷氧基羰基氨基、烷氧基羰基、芳基或杂环烷基取代基;其中-NR5-CR6R16-Q1-R10是氨基酸残基,R5、R6和R16在权利要求1中定义,其中Q1和Q2可以相同或不同,各自是羰基(-CO-)或亚甲基(-CH2-);其中R10和R20可以相同或不同,是羟基、氨基或其取代衍生物或羟基氨基或芳硫基;或其适当的盐;其制造工艺和含有它们的药物组合物。这些化合物是血管紧张素转换酶的抑制剂,可用于治疗高血压。
  • PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF
    申请人:Cook, Timothy, H.
    公开号:EP3762377A1
    公开(公告)日:2021-01-13
  • PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF
    申请人:Hla Timothy
    公开号:US20200407339A1
    公开(公告)日:2020-12-31
    The various examples presented herein are directed to compounds of the formula A-L 1 -Het 1 -L 2 -Cy 1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het 1 is heterocyclyl containing at least two heteroatoms; Cy 1 is a heterocyclyl; L 1 is a bond, alkyl, alkenyl or alkynyl linker; L 2 is an acyl or alkyl linker; and A and Cy 1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.
  • US4528282A
    申请人:——
    公开号:US4528282A
    公开(公告)日:1985-07-09
  • [EN] PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS À BASE DE PYRIDINONE ET DE PYRIDAZINONE ET UTILISATIONS MÉDICALES ASSOCIÉES
    申请人:HLA TIMOTHY
    公开号:WO2019173790A1
    公开(公告)日:2019-09-12
    The various examples presented herein are directed to compounds of the formula A-L1-Het1-L2-Cy1 or a pharmaceutical acceptable salt, polymorph, prodrug, solvate or clathrate thereof, wherein: A is cycloalkyl, aryl, arylalkyl or heterocyclyl; Het1 is heterocyclyl containing at least two heteroatoms; Cy1 is a heterocyclyl; L1 is a bond, alkyl, alkenyl or alkynyl linker; L2 is an acyl or alkyl linker; and A and Cy1 are different. The compounds are useful in the treatment of fibrotic diseases, abnormal vascular leak and pathological angiogenesis.
    本文提供的各种示例涉及到以下公式的化合物A-L1-Het1-L2-Cy1或其药用可接受的盐、多型体、前药、溶剂合物或包合物,其中:A为环烷基、芳基、芳基烷基或杂环烷基;Het1为含有至少两个杂原子的杂环烷基;Cy1为杂环烷基;L1为键、烷基、烯基或炔基连接物;L2为酰基或烷基连接物;A和Cy1不同。这些化合物在治疗纤维化疾病、异常血管渗漏和病理性血管生成方面具有用途。
查看更多